Business Standard
Friday, Jun 01, 2012
Sponsored by  
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
|||||Opinion|||| 
 Section Home | Editorials | Compass | BS People | Columnists | Lunch with BS
Home > Opinion & Analysis Live Markets | Commodities
 

Sreelatha Menon: In praise of opium
Absence of govt policy on treatment of pain and a draconian law deny lakhs of cancer patients morphine which often is the only remedy for pain
Sreelatha Menon / New Delhi Nov 01, 2009, 01:04 IST

“Relieve my pain or let me die,” said a patient at Hyderabad cancer hospital, writhing with pain. This sentiment is felt by most patients suffering acute pain. While there is remedy to prolong the life of patients suffering from terminal illnesses like cancer, a majority of doctors provide no treatment for pain. Of the 1.2 million cancer patients who die annually in the country, 80 per cent suffer severe pain. In most cases, a bit of morphine is the only remedy.

But it is a banned substance under the narcotics law and hence not easily available even for medical treatment.

Poet John Keats often wrote immortal lines in pain from tuberculosis, and for him, as for many artistes, the cure was some morphine, or “dull opiate’’ (it made his pain dull), as he called it

But in India, though morphine is cultivated and even exported for palliative care abroad, there is none available for patients in India due to a law that ignores the sick and also due to absence of a policy on palliative care.

A recent report by the Human Rights Watch accuses India of gross violation of human rights by denying patients morphine.

Here is the irony. Morphine is banned. And even if it was not, our doctors wouldn’t know what to do with it as their text books never taught them how to relieve pain.

The narcotics Act makes it illegal to possess morphine, which is the only remedy for pain in a majority of cancer cases. A model legislation was issued by the finance ministry years ago but only 14 states bothered to carry out the amendment.

But even this amendment, which makes it easy to get a licence to buy morphine, is futile.

The reason is that Indian medical colleges do not teach doctors how to lessen pain. The Human Rights Watch asks governments to draft a policy on palliative care. It also asks for inclusion of palliative care in the medical curriculum.

It is not as if the government has been blind to the agony of patients. It once took funds from the World Health Organisation, which is a forceful advocate of palliative care, and bought huge quantities of morphine between 1996 and 2003. But this morphine remained in a room in Kolkata’s Chittaranjan National Cancer Institute as regional cancer hospitals refused to take it, said the Human Rights Watch

Not all states in the country are blind to the plight of the people. In fact, when some enlightened doctors joined hands with the government in Kerala, what was achieved was a unique state-wide network of palliative care providers funded by the state and local communities.

Dr MR Rajagopal, director of Trivandrum Institute of Palliative Sciences and chairman of Pallium India, an NGO which wrought this miracle in Kerala, however, is not satisfied. He said the ideal would be palliative care becoming integrated with cancer treatment. For the disease cannot be separated from its pain. For this to happen, the Medical Council of India has to wake up and change the curriculum.

For Rajagopal and his colleagues, the struggle has just begun.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets post worst May performace since 2006
- Kavveri Telecom Q4 net declines over 6%
- Wall Street opens flat on economy worries
- RIM to set up first BlackBerry innovation zone in India
- Rajaratnam bragged about sources of inside info: Gupta lawyers
  Read Business news in 
- Help a Child Achieve her. Click to know more
- Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol.
- Watch The Film Here. Click here to know more..
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- One Partnership Endless Possibilities. Click here to know more
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- Invest in Real Estate. Villas in Bangalore starting @ Rs.66 lacs
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- Slowdown gets worse, GDP growth sinks to 9-year low
- India to be $2-trn economy by FY13-end?
- India Inc ready to shift to other side of the dot on www
- Bharat Bandh sussessful in Chhattisgarh
- IIT alumni to move court on changes in JEE
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
  Hot Searches  
 
Apalya |  Air India |  GAAR |  Agni  |  Solar eclipse |  Satyamev Jayate |  SRK |  Aamir Khan |  IPL |  Ertiga |  Sarfaesi Act |  Vodafone |  JP Morgan |  Transfer pricing |  Rupee |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us